Baptiste Baylac-Paouly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Baptiste Baylac-Paouly has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jan Hendriks
Netherlands Vaccine Institute, Bilthoven, the Netherlands
1 shared publication María-Isabel Porras
Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain
1 shared publicationMaría-Victoria Caballero
Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain
1 shared publication- Stuart Blume
Vrije Universiteit Amsterdam, Amsterdam, Netherlands
1 shared publication
Latest Publications
- 1 April 2022
- Published by Cambridge University Press (CUP) in Medical History
- Vol. 66 (2) , 135-154
Mobilising through vaccination: the case of polio in France (1950–60s)
Poliomyelitis is a disease whose incidence steadily increased during the second half of the twentieth century on both sides of the Atlantic. If in the United States the epidemics which afflicted young children each summer became a major public health issue, in France, polio was considered less pressing than other diseases. This article, based on original archives from the Pasteur and Mérieux institutes, analyses the polio control strategies and policies implemented by France from the mid-1950s to the end of the 1960s. The article examines the role of two key actors and institutions that mobilised the French health authorities against the disease: Pierre Lépine and the Institut Pasteur as well as Charles Mérieux and the Institut Mérieux. Lépine developed an effective injected polio vaccine which was first used before being supplemented with the oral polio vaccine. If the two main protagonists and their institutions worked together, they each implemented different actions and manoeuvres, at different times with the aim to raise awareness of the fight against the disease. The national and international relations of the key French actors were decisive in the development and production of the polio vaccines and their application. This work contributes to understanding processes of polio vaccines choice at the level of national institutions and analyses the political and scientific networks built in support of polio vaccination, to finally move towards compulsory vaccination. Ultimately, this study describes the historical processes by which this disease became conflated with a biotechnology of collective protection in France.
- 1 April 2022
- Published by Cambridge University Press (CUP) in Medical History
- Vol. 66 (2) , 135-154
Mobilising through vaccination: the case of polio in France (1950–60s)
Poliomyelitis is a disease whose incidence steadily increased during the second half of the twentieth century on both sides of the Atlantic. If in the United States the epidemics which afflicted young children each summer became a major public health issue, in France, polio was considered less pressing than other diseases. This article, based on original archives from the Pasteur and Mérieux institutes, analyses the polio control strategies and policies implemented by France from the mid-1950s to the end of the 1960s. The article examines the role of two key actors and institutions that mobilised the French health authorities against the disease: Pierre Lépine and the Institut Pasteur as well as Charles Mérieux and the Institut Mérieux. Lépine developed an effective injected polio vaccine which was first used before being supplemented with the oral polio vaccine. If the two main protagonists and their institutions worked together, they each implemented different actions and manoeuvres, at different times with the aim to raise awareness of the fight against the disease. The national and international relations of the key French actors were decisive in the development and production of the polio vaccines and their application. This work contributes to understanding processes of polio vaccines choice at the level of national institutions and analyses the political and scientific networks built in support of polio vaccination, to finally move towards compulsory vaccination. Ultimately, this study describes the historical processes by which this disease became conflated with a biotechnology of collective protection in France.
- 14 October 2021
- Published by Oxford University Press (OUP) in Social History of Medicine
- Vol. 35 (1) , 1-19
Polio Vaccine Struggles: FAIR and the Failed Reintroduction of Inactivated Polio Vaccine, 1975–1985
Summary: This article discusses the strategies and trajectories deployed by the Forum for the Advancement of Immunization Research (FAIR) to rehabilitate Salk’s inactivated polio vaccine (IPV), at a time when Sabin’s oral polio vaccine (OPV) had come to dominate the global polio vaccine market. FAIR was an international coalition of scientists and institutions that undertook specific field studies to establish the conditions under which IPV could usefully be introduced in developing countries. Regardless of the evidence it gathered, FAIR failed to convince WHO to integrate IPV into the Expanded Programme on Immunization (EPI). This study of the life of IPV vaccine beyond its initial development and introduction, provides insights in the interplay of evidence and interests in the political decisions made around vaccination.
- 14 October 2021
- Published by Oxford University Press (OUP) in Social History of Medicine
- Vol. 35 (1) , 1-19
Polio Vaccine Struggles: FAIR and the Failed Reintroduction of Inactivated Polio Vaccine, 1975–1985
Summary: This article discusses the strategies and trajectories deployed by the Forum for the Advancement of Immunization Research (FAIR) to rehabilitate Salk’s inactivated polio vaccine (IPV), at a time when Sabin’s oral polio vaccine (OPV) had come to dominate the global polio vaccine market. FAIR was an international coalition of scientists and institutions that undertook specific field studies to establish the conditions under which IPV could usefully be introduced in developing countries. Regardless of the evidence it gathered, FAIR failed to convince WHO to integrate IPV into the Expanded Programme on Immunization (EPI). This study of the life of IPV vaccine beyond its initial development and introduction, provides insights in the interplay of evidence and interests in the political decisions made around vaccination.
- 30 May 2021
- p. 1-3
Book of epidemics
- 31 December 2019
- Published by Oxford University Press (OUP) in Social History of Medicine
- Vol. 34 (2) , 632-649
Confronting an Emergency: The Vaccination Campaign Against Meningitis in Brazil (1974–1975)
Summary On the basis of a wide range of historical sources, including published scientific literature and both public and private archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the Brazilian vaccination campaign against cerebrospinal meningitis between 1974 and 1975. It explores not only certain aspects of vaccine production but also the wider social aspects of the ongoing project. Thus, it shows how the different actors were mobilised and their work coordinated in order to produce and vaccinate a whole country or more specifically, 90 million Brazilians in less than a year. This episode not only adds to the scholarship on the politics of vaccination but also attests to the complex reality of the production and use of a vaccine in the context of a public health emergency.
- 31 December 2019
- Published by Oxford University Press (OUP) in Social History of Medicine
- Vol. 34 (2) , 632-649
Confronting an Emergency: The Vaccination Campaign Against Meningitis in Brazil (1974–1975)
Summary On the basis of a wide range of historical sources, including published scientific literature and both public and private archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the Brazilian vaccination campaign against cerebrospinal meningitis between 1974 and 1975. It explores not only certain aspects of vaccine production but also the wider social aspects of the ongoing project. Thus, it shows how the different actors were mobilised and their work coordinated in order to produce and vaccinate a whole country or more specifically, 90 million Brazilians in less than a year. This episode not only adds to the scholarship on the politics of vaccination but also attests to the complex reality of the production and use of a vaccine in the context of a public health emergency.
- 1 July 2019
- Published by Cambridge University Press (CUP) in Medical History
- Vol. 63 (4) , 435-453
Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969–73)
Based on a wide range of historical sources, including published scientific literature and archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the development of the meningococcal A vaccine between 1969 and 1973. It explores the social factors of vaccine development including various collaborations, informal discussions, the circulation of products and materials, formal meetings, trials and setbacks to highlight the complex reality of the development, production and use of the vaccine. Inscribed in a ‘Golden Age’ of vaccine development and production, this episode not only adds to the scholarship on the history of vaccines, which has tended to focus on a narrative of progress, but also considers the sharing of knowledge through collaborations, and the risks involved in the development of a vaccine. Finally, this perspective reveals the uncertainties and difficulties underlying the production of an effective vaccine.
- 1 July 2019
- Published by Cambridge University Press (CUP) in Medical History
- Vol. 63 (4) , 435-453
Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969–73)
Based on a wide range of historical sources, including published scientific literature and archives (Institut Mérieux, WHO and IMTSSA), this article examines the history of the development of the meningococcal A vaccine between 1969 and 1973. It explores the social factors of vaccine development including various collaborations, informal discussions, the circulation of products and materials, formal meetings, trials and setbacks to highlight the complex reality of the development, production and use of the vaccine. Inscribed in a ‘Golden Age’ of vaccine development and production, this episode not only adds to the scholarship on the history of vaccines, which has tended to focus on a narrative of progress, but also considers the sharing of knowledge through collaborations, and the risks involved in the development of a vaccine. Finally, this perspective reveals the uncertainties and difficulties underlying the production of an effective vaccine.